Soligenix, Inc. (LON:0A6I)
2.360
-0.065 (-2.70%)
At close: Feb 18, 2025
Soligenix Employees
As of December 31, 2023, Soligenix had 15 total employees, including 13 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
15
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
19.41K GBP
Profits / Employee
-378.33K GBP
Market Cap
4.82M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
Shell | 103,000 |
HSBC Holdings | 220,861 |
Unilever | 128,377 |
Rio Tinto Group | 57,000 |
RELX PLC | 36,400 |
BP p.l.c. | 87,800 |
British American Tobacco p.l.c. | 46,725 |
Soligenix News
- 19 days ago - Soligenix to Present at BIO CEO & Investor Conference - PRNewsWire
- 5 weeks ago - Soligenix to Present at Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma - Benzinga
- 5 weeks ago - HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer - Benzinga
- 2 months ago - HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment - PRNewsWire
- 3 months ago - Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire